April 18, 2019: lamivudine/raltegravir for PrEP; feminizing hormone may impact PrEP efficacy; why TAF has a better renal profile than TDF; the role of internet dating in HIV incidence trends.
E/C/F/TAF viability for dialysis patients; TAF safety following renal damage; mental health needs for American Indians; parenting desires of people with HIV.
Switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) improved kidney and bone markers in a study focused on people 50 years old or older.
Each additional year of tenofovir disoproxil fumarate, ritonavir-boosted atazanavir or lopinavir was independently linked to higher incidence of chronic kidney disease in a 23,905-person cohort with initially normal renal function.
In general, tenofovir alafenamide (TAF) is safe, with improvements in bone and kidney health over tenofovir disoproxil fumarate (TDF). However, those with severe kidney disease may not see improvements in kidney health, according to a recent study....
A new single-tablet HIV regimen containing tenofovir alafenamide (TAF) offered better bone and kidney safety, according to a study presented at ICAAC/ICC 2015.
The new formulation of tenofovir, tenofovir alafenamide (TAF), was associated with less harm to bones and kidneys than the older formulation, tenofovir disoproxil fumarate (TDF, Viread).
Renal dysfunction was more likely in patients who had taken tenofovir (Truvada, TDF) longer, were older, or also had diabetes or hypertension, according to a study presented at IDWeek 2014.
Researchers from UCL reported on a ptoential early marker for tenofovir-associated renal toxicity.
Ana Milinkovic and colleagues from University College London, presented results from routine monitoring for tenofovir-related renal toxicity which sin...
Tenofovir is one of the most widely used antiretrovirals and the association with a generally low risk of renal complications has been widely reported. However, there has been conflicting data on potential for renal complications with cumulative use ...